Fosinopril angiotensin-Converting Enzyme Inhibitors

Description Results NMA

fosinopril (n=142)

vs.

placebo (n=143)

double blind

Parallel groups

Sample size: 142/143

Primary endpoint: LV volumes

FU duration: 2 years

fosinopril 10 or 20 mg/day (n=116)

vs.

placebo (n=125)

double blind

Sample size: 116/125

Primary endpoint: exercise tolerance

FU duration: 24 weeks

fosinopril 40 mg once daily titrated (n=155)

vs.

placebo (n=153)

double blind

Sample size: 155/153

Primary endpoint: maximal bicycle exercise time

FU duration: 12 weeks

all cause mortality 1.09 [0.78; 1.52]

Cardiovascular mortality 1.06 [0.67; 1.68]

cardiovascular event 1.15 [0.86; 1.53]

Fosinopril 20 mg/day (n=196)

vs.

matched placebo (n=201)

double blind

Sample size: 196/201

Primary endpoint:

FU duration: 24 months